ETON - Eton Pharmaceuticals Inc logo

Eton Pharmaceuticals Inc

ETON

Eton Pharmaceuticals develops and commercializes treatments for rare diseases, offering products like Increlex, Alkindi Sprinkle, and Nitisinone. The company also has late-stage candidates addressing conditions such as diabetes insipidus and Wilson disease.

โš•๏ธ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 5 years ago โ†’$9,078today

Score Overview

1 Year
Score
Net Growth375.77%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth32.08%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score6.5
Net Growth8x
Net Trend40%
Net Income Consistencyโ€”
Rev Growth383.67%
Rev Trend80%
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth199.59%
Net Trend38%
Net Income Consistency
Rev Growthโ€”
Rev Trend83%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Eton Pharmaceuticals Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. ETON does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 50.02โ€”
1 Year2025-10-22
$ 18.66168.06%
5 Years2021-10-22
$ 5.519x
All Time2018-11-13
$ 6.258x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 105M$ 12M$ 26M
2025$ 79M-$ 4M$ 25M
2024$ 39M-$ 3M$ 14M
2023$ 31M-$ 936K$ 21M
2022$ 21M-$ 9M$ 16M
2021$ 21M-$ 1M$ 14M
2020-$ 27M$ 21M
2019$ 959K-$ 18M$ 12M
IPO2018$ 0.00-$ 12M$ 26M
ETON - Eton Pharmaceuticals Inc logo

Eton Pharmaceuticals Inc fundamental performance

Between 2020 and 2025, net income went from -$ 27M to -$ 4M. Revenue increased in 4 of those 5 years; net income in 2.

Eton Pharmaceuticals Inc currently holds a 5-year HDB Score of 6.5 out of 10. How the HDB Score is calculated.

Membership

Explore ETON with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies